Clariant AG (CLZNY)
Valor JustoFundamental
49
Precio
$10.45
Capitalización Bursátil
$3.55B
Parte 1 · Cuánto vale la empresa
Resumen
Clariant makes specialty chemicals — ingredients and additives that go into other companies' products rather than finished goods sold directly to consumers. Its formulations end up in shampoos, detergents and cosmetics, in catalysts that refineries and chemical plants use to run reactions more efficiently, and in additives that keep plastics, coatings and other materials stable. Customers are industrial and consumer-goods manufacturers who need a specific chemical property, not a brand name.
Cómo genera ingresos
Revenue comes from selling formulated chemicals by volume at prices that reflect both the cost of raw materials — often oil-derived — and the performance the formulation delivers, so pricing power varies a lot by product: a proprietary catalyst commands a different margin than a commodity-like additive. The business runs through three units — Care Chemicals, Catalysts, and Adsorbents & Additives — each selling into different end industries with different demand cycles.
Qué impulsa la demanda
Moderadamente cíclicoCare Chemicals sells mostly into personal care and household products, which hold up reasonably well in a downturn, while Catalysts and Adsorbents & Additives depend more on industrial output and energy-sector investment, which is more sensitive to the economic cycle. The mix of the three units softens, but does not eliminate, Clariant's exposure to industrial demand swings.
Los argumentos a favor
Buyers argue that specialty formulations command better margins than commodity chemicals, that the EBITDA margin has improved for three straight years even as reported sales declined, and that a more focused three-unit portfolio after years of divestitures lets management run the business more efficiently.
Los argumentos en contra
Sellers fear that flat-to-declining sales in local currency show weak underlying demand that margin gains from cost cutting cannot offset forever, that currency translation can erode reported results even when the underlying business is stable, and that Catalysts and Adsorbents & Additives remain exposed to industrial and energy cycles outside the company's control.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
BASF is the only rival that meets Clariant in all three of its business units at once, selling personal- and home-care ingredients, process catalysts for syngas and petrochemicals, and adsorbents to the same industrial buyers.
Evonik's Consumer Specialties and Coatings & Additives units sell surfactants and care ingredients to the same cosmetics, detergent and coatings formulators that Clariant's Care Chemicals and Additives businesses supply.
Croda competes head-on with Clariant's Care Chemicals unit in surfactants and speciality ingredients for personal care and crop protection formulations.
Lanxess sells flame retardants, lubricant additives and preservatives for home and personal care into the same additive and consumer-protection markets as Clariant's Additives business.
Spun out of AkzoNobel and privately held, Nouryon supplies surfactants and speciality ingredients for cleaning, personal care and agriculture, bidding for the same formulator accounts as Clariant Care Chemicals.
Balance y Liquidez
Ingresos
$3.77B
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Beneficio Neto
$-31M
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Flujo de Caja Libre
$214M
Patrimonio Neto Total
$2.02B
Pasivo Total
$2.13B
Ratio de Liquidez
1.77
Cobertura de Intereses
-
Deuda/EBITDA
3.77
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$9.86
Precio Actual
$10.45
Margen de Seguridad
-6.0%
Rango de Valor Justo
$9.26 - $10.47
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-0.0%
Ratio P/B
1.74
P/FCF
16.53
Margen Bruto
31.0%
ROIC
7.6%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
7.6%
WACC
6.6%
ROIC − WACC
+1.0 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (10)
- ROIC 7.6%
- Gross Margin 31.0%
- P/FCF 16.53
- P/B Ratio 1.74
- Debt/Equity ratio
- Operating Margin 10.7%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Analyst Consensus 59% Buy
Fallido (8)
- Price CAGR -5.32%
- CapEx intensity
- DCF valuation (Fairly valued)
- ROE -1.5%
- Revenue Growth 5Y 0.3%
- Earnings Surprise avg -6.6%
- Net Margin Trend -1.9% vs 5.9%
- Piotroski F-Score 2/9
No disponible (9)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
No hay declaraciones institucionales para esta empresa.
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Conrad Keijzer | Chief Executive Officer | 57 |
| Mr. Oliver Rittgen | Chief Financial Officer | - |
| Mr. Richard Haldimann Ph.D. | Chief Strategy & Technology Officer | - |
| Mr. Andreas Schwarzwaelder | Head of Investor Relations | - |
| Dr. Judith Bischoff | General Counsel & Head of Group Legal Services | 51 |
| Kai Rolker | Head of Group Communications | - |
| Priya Thaman | Chief Human Resources Officer | - |
| Mr. Joachim Krüger | Head of Corporate Sustainability & Regulatory Affairs | - |
| Monica Ferreira | Region Head of Latin America | - |
| Mr. Christian Vang | President of BU Care Chemicals & Americas Region | - |
Riesgo de Auditoría
10
Riesgo del Consejo
1
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
9
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for CLZNY, sourced from Markets Gazette.